Rationale and targets for antifibrotic therapies

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 10-11, 2009, Pages 949-957

  Schuppan, D ^a   Popov, Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; BILE ACID; CANNABINOID 1 RECEPTOR ANTAGONIST; CYTOKINE RECEPTOR ANTAGONIST; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLAVONOID; GLITAZONE DERIVATIVE; HALOFUGINONE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERSTITIAL COLLAGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL COLLAGENASE; PIOGLITAZONE; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; RAPAMYCIN; ROSIGLITAZONE; SILIBININ; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ALCOHOLIC FATTY LIVER; APOPTOSIS; AUTOIMMUNE HEPATITIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FIBROGENESIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NONVIRAL GENE THERAPY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; SHORT SURVEY; STEM CELL TRANSPLANTATION; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INHIBITORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; STEM CELL TRANSPLANTATION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70350617790     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.07.021     Document Type: Short Survey

References (92)

1. Schuppan D., Ruehl M., Somasundaram R., and Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Sem Liver Dis 21 (2001) 351-372
2. Friedman S.L. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 98-105
3. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 (2005) 209-218
4. Schuppan D., and Afdhal N.H. Liver cirrhosis. Lancet 371 (2008) 838-851
5. Li Z., Dranoff J.A., Chan E.P., Uemura M., Sévigny J., and Wells R.G. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 46 (2007) 1246-1256
6. Benyon R.C., and Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 21 (2001) 373-384
7. Iredale J.P. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 29 (2001) 43-54
8. Knittel T., Kobold D., Saile B., Grundmann A., Neubauer K., Piscaglia F., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117 (1999) 1205-1221
9. Kisseleva T., Uchinami H., Feirt N., Quintana-Bustamante O., Segovia J.C., Schwabe R.F., et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 45 (2006) 429-438
10. Higashiyama R., Inagaki Y., Hong Y.Y., Kushida M., Nakao S., Niioka M., et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 45 (2007) 213-222
11. Kaimori A., Potter J., Kaimori J.Y., Wang C., Mezey E., and Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282 (2007) 22089-22101
12. Zeisberg M., Yang C., Martino M., Duncan M.B., Rieder F., Tanjore H., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282 (2007) 23337-23347
13. Clouston A.D., Powell E.E., Walsh M.J., Richardson M.M., Demetris A.J., and Jonsson J.R. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 41 (2005) 809-818
14. Lowes K.N., Brennan B.A., Yeoh G.C., and Olynyk J.K. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 154 (1999) 537-541
15. Pinzani M., Milani S., Herbst H., DeFranco R., Grappone C., Gentilini A., et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 148 (1996) 785-800
16. Milani S., Herbst H., Schuppan D., Stein H., and Surrenti C. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 139 (1991) 1221-1229
17. Sedlaczek N., Jia J.D., Bauer M., Herbst H., Ruehl M., Hahn E.G., et al. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. Am J Pathol 158 (2001) 1239-1244
18. Strazzabosco M., Spirli C., and Okolicsanyi L. Pathophysiology of the intrahepatic biliary epithelium. J Gastroenterol Hepatol 15 (2000) 244-253
19. Milani S., Herbst H., Schuppan D., Kim K.Y., Riecken E.O., and Stein H. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology 98 (1990) 175-184
20. Omenetti A., Popov Y., Jung Y., Choi S.S., Witek R.P., Yang L., et al. The hedgehog pathway regulates remodeling responses to biliary obstruction in rats. Gut 57 (2008) 1275-1282
21. Omenetti A., Porrello A., Jung Y., Yang L., Popov Y., Choi S.S., et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 118 (2008) 3331-3342
22. Bissell D.M., Roulot D., and George J. Transforming growth factor beta and the liver. Hepatology 34 (2001) 859-867
23. Gressner A.M., Weiskirchen R., Breitkopf K., and Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7 (2002) d793-807
24. Issa R., Zhou X., Constandinou C.M., Fallowfield J., Millward-Sadler H., Gaca M.D., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126 (2004) 1795-1808
25. Issa R., Williams E., Trim N., Kendall T., Arthur M.J., Reichen J., et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 (2001) 548-557
26. Soyer M.T., Ceballos R., and Aldrete J.S. Reversibility of severe hepatic damage caused by jejunoileal bypass after re-establishment of normal intestinal continuity. Surgery 79 (1976) 601-604
27. Hammel P., Couvelard A., O'Toole D., Ratouis A., Sauvanet A., Fléjou J.F., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344 (2001) 418-423
28. Dufour J.F., DeLellis R., and Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127 (1997) 981-985
29. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
30. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
31. Poynard T., McHutchison J., Manns M., Farrell G., Lee C.Z., Yuen H., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
32. Friedman S.L., and Bansal M.B. Reversal of hepatic fibrosis - fact or fantasy?. Hepatology 43 2 Suppl. 1 (2006) S82-S88
33. Langholz O., Röckel D., Mauch C., Kozlowska E., Bank I., Krieg T., et al. Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. J Cell Biol 131 (1995) 1903-1915
34. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115 (2005) 56-65
35. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 (1998) 842-845
36. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125 (2003) 1085-1093
37. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38 (2003) 1468-1476
38. Satsangi J., Chapman R.W., Haldar N., Donaldson P., Mitchell S., Simmons J., et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology 121 (2001) 124-130
39. Wright M., Goldin R., Hellier S., Knapp S., Frodsham A., Hennig B., et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 52 (2003) 1206-1210
40. Yoshizawa K., Ota M., Saito S., Maruyama A., Yamaura T., Rokuhara A., et al. Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens 61 (2003) 159-165
41. Erhardt A., Maschner-Olberg A., Mellenthin C., Kappert G., Adams O., Donner A., et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 38 (2003) 335-342
42. Silvestri L., Sonzogni L., De Silvestri A., Gritti C., Foti L., Zavaglia C., et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 104 (2003) 310-317
43. Stickel F., Osterreicher C.H., Datz C., Ferenci P., Wölfel M., Norgauer W., et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med 165 (2005) 1835-1840
44. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008) 1461-1465
45. Huang H., Shiffman M.L., Friedman S., Venkatesh R., Bzowej N., Abar O.T., et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46 (2007) 297-306
46. Fernández M., Semela D., Bruix J., Colle I., Pinzani M., and Bosch J. Angiogenesis in liver disease. J Hepatol 50 (2009) 604-620
47. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614-2618
48. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
49. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
50. Patsenker E., Popov Y., Stickel F., Jonczyk A., Goodman S.L., and Schuppan D. Inhibition of Integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis Progression. Gastroenterology 135 (2008) 660-670
51. Popov Y., Patsenker E., Fickert P., Trauner M., and Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol 43 (2005) 1045-1054
52. Popov Y., Patsenker E., Bauer M., Niedobitek E., Schulze-Krebs A., and Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem 281 (2006) 15090-15098
53. Ota T., Takamura T., Kurita S., Matsuzawa N., Kita Y., Uno M., et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132 (2007) 282-293
54. Pinzani M., Rombouts K., and Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 Suppl. 1 (2005) S22-36
55. Rockey D.C. Current and future antifibrotic therapies for chronic liver disease. Clin Liver Dis 12 (2008) 939-962
56. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008) 1655-1669
57. Qi Z., Atsuchi N., Ooshima A., Takeshita A., and Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 96 (1999) 2345-2349
58. George J., Roulot D., Koteliansky V.E., and Bissell D.M. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 96 (1999) 12719-12724
59. Yata Y., Gotwals P., Koteliansky V., and Rockey D.C. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35 (2002) 1022-1030
60. Milani S., Herbst H., Schuppan D., Stein H., and Surrenti C. Transforming growth factors β1 and β2 are differentially expressed in fibrotic liver disease. Am J Pathol 139 (1991) 1221-1229
61. Popov Y., Patsenker E., Stickel F., Zaks J., Bhaskar K.R., Niedobitek G., et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 48 (2008) 453-464
62. Wang B., Dolinski B.M., Kikuchi N., Leone D.R., Peters M.G., Weinreb P.H., et al. Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 46 (2007) 1404-1412
63. Bruck R., Genina O., Aeed H., Alexiev R., Nagler A., Avni Y., et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33 (2001) 379-386
64. Iimuro Y., Nishio T., Morimoto T., Nitta T., Stefanovic B., Choi S.K., et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124 (2003) 445-458
65. Siller-Lopez F., Sandoval A., Salgado S., Salazar A., Bueno M., Garcia J., et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126 (2004) 1122-1133
66. De Bleser P.J., Xu G., Rombouts K., Rogiers V., and Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J Biol Chem 274 (1999) 33881-33887
67. Garcia-Trevijano E.R., Iraburu M.J., Fontana L., Domínguez-Rosales J.A., Auster A., Covarrubias-Pinedo A., et al. Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 29 (1999) 960-970
68. Jia J.D., Bauer M., Cho J.J., Ruehl M., Milani S., Boigk G., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen I TIMP-1 and TGF-β1 RNA. J Hepatol 35 (2001) 392-398
69. Shimizu I., Ma Y.R., Mizobuchi Y., Liu F., Miura T., Nakai Y., et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 29 (1999) 282-284
70. Galli A., Crabb D.W., Ceni E., Salzano R., Mello T., Svegliati-Baroni G., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122 (2002) 1924-1940
71. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004) 1497-1512
72. Czaja M.J. Pioglitazone: more than just an insulin sensitizer. Hepatology 49 (2009) 1427-1430
73. Cho J.J., Hocher B., Herbst H., Jia J.D., Ruehl M., Hahn E.G., et al. An oral endothelin A receptor antagonist blocks collagen synthesis and deposition in advanced rat secondary fibrosis. Gastroenterology 118 (2000) 1169-1178
74. Paizis G., Gilbert R.E., Cooper M.E., Murthi P., Schembri J.M., Wu L.L., et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35 (2001) 376-385
75. Croquet V., Moal F., Veal N., Wang J., Oberti F., Roux J., et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 37 (2002) 773-780
76. Moreno M., and Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis 12 (2008) 825-852
77. Morath C., and Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 41 (2003) 465-469
78. Zhu J., Wu J., Frizell E., Liu S.L., Bashey R., Rubin R., et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117 (1999) 1198-1204
79. Rombouts K., Kisanga E., Hellemans K., Wielant A., Schuppan D., and Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38 (2003) 564-572
80. Tugues S., Fernandez-Varo G., Munoz-Luque J., Ros J., Arroyo V., Rodes J., et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46 (2007) 1919-1926
81. Beljaars L., Weert B., Geerts A., Meijer D.K., and Poelstra K. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 66 (2003) 1307-1317
82. Beljaars L, Molema G, Schuppan D, Geerts A, De Bleser PJ, Weert B, et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 2000;275:12743-51.
83. Greupink R., Bakker H.I., Reker-Smit C., van Loenen-Weemaes A.M., Kok R.J., Meijer D.K., et al. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol 43 (2005) 884-892
84. Hagens W.I., Beljaars L., Mann D.A., Wright M.C., Julien B., Lotersztajn S., et al. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. J Pharmacol Exp Ther 324 (2008) 902-910
85. Douglass A., Wallace K., Parr R., Park J., Durward E., Broadbent I., et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 49 (2008) 88-98
86. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 26 (2008) 431-442
87. Kobayashi N., Ito M., Nakamura J., Cai J., Gao C., Hammel J.M., et al. Hepatocyte transplantation in rats with decompensated cirrhosis. Hepatology 31 (2000) 851-857
88. Malhi H., Irani A.N., Gagandeep S., and Gupta S. Isolation of human progenitor liver epithelial cells with extensive replication capacity and differentiation into mature hepatocytes. J Cell Sci 115 (2002) 2679-2688
89. Vassilopoulos G., Wang P.R., and Russell D.W. Transplanted bone marrow regenerates liver by cell fusion. Nature 422 (2003) 901-904
90. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 39 (2004) 1477-1487
91. Nowak G., Ericzon B.G., Nava S., Jaksch M., Westgren M., and Sumitran-Holgersson S. Identification of expandable human hepatic progenitors which differentiate into mature hepatic cells in vivo. Gut 54 (2005) 972-979
92. Thorgeirsson S.S., and Grisham J.W. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 43 (2006) 2-8